Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis A Systematic Review

被引:61
|
作者
Mueller, Jannis [1 ,2 ,3 ,4 ]
Cagol, Alessandro [1 ,2 ,3 ]
Lorscheider, Johannes [1 ,2 ,4 ]
Tsagkas, Charidimos [1 ,2 ,3 ,4 ]
Benkert, Pascal [5 ]
Yaldizli, Ozgur [1 ,2 ,3 ,4 ]
Kuhle, Jens [1 ,2 ,4 ]
Derfuss, Tobias [1 ,2 ,4 ]
Sormani, Maria Pia [6 ,7 ]
Thompson, Alan [8 ,9 ]
Granziera, Cristina [1 ,2 ,3 ,4 ]
Kappos, Ludwig [1 ,2 ,3 ,10 ]
机构
[1] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[2] Univ Basel, Basel, Switzerland
[3] Univ Hosp Basel, Fac Med, Dept Biomed Engn, Translat Imaging Neurol ThINK Basel, Basel, Switzerland
[4] Univ Hosp Basel, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland
[5] Univ Basel, Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland
[6] IRCCS Osped Policlin San Martino, Dept Hlth Sci, I-16132 Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Genoa, Italy
[8] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[9] NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England
[10] Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Spitalstr 2, CH-4031 Basel, Switzerland
关键词
DISABILITY PROGRESSION; ONSET; PIRA; ACCUMULATION; OCRELIZUMAB; AGE;
D O I
10.1001/jamaneurol.2023.3331
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ImportanceEmerging evidence suggests that progression independent of relapse activity (PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (RRMS). To date, there is no uniform agreed-upon definition of PIRA, limiting the comparability of published studies.ObjectiveTo summarize the current evidence about PIRA based on a systematic review, to discuss the various terminologies used in the context of PIRA, and to propose a harmonized definition for PIRA for use in clinical practice and future trials.Evidence ReviewA literature search was conducted using the search terms multiple sclerosis, PIRA, progression independent of relapse activity, silent progression, and progression unrelated to relapses in PubMed, Embase, Cochrane, and Web of Science, published between January 1990 and December 2022.FindingsOf 119 identified single records, 48 eligible studies were analyzed. PIRA was reported to occur in roughly 5% of all patients with RRMS per annum, causing at least 50% of all disability accrual events in typical RRMS. The proportion of PIRA vs relapse-associated worsening increased with age, longer disease duration, and, despite lower absolute event numbers, potent suppression of relapses by highly effective disease-modifying therapy. However, different studies used various definitions of PIRA, rendering the comparability of studies difficult.Conclusion and RelevancePIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional MS phenotypes, including clinically isolated syndrome and early RRMS. The harmonized definition suggested here may improve the comparability of results in current and future cohorts and data sets.
引用
收藏
页码:1232 / 1245
页数:14
相关论文
共 50 条
  • [21] Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
    Bsteh, G.
    Hegen, H.
    Altmann, P.
    Berek, K.
    Wurth, S.
    Auer, M.
    Zinganell, A.
    Di Pauli, F.
    Rommer, P.
    Leutmezer, F.
    Deisenhammer, F.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 188 - 189
  • [22] Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis
    Kappos, Ludwig
    Montalban, Xavier
    Coyle, Patricia
    Nicholas, Jacqueline
    Meuth, Sven
    Li, Bingbing
    Ramanathan, Krishnan
    Su, Wendy
    Willi, Roman
    Haering, Dieter A.
    Hauser, Stephen
    NEUROLOGY, 2021, 96 (15)
  • [23] Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis
    Ciccarelli, Olga
    Barkhof, Frederik
    Calabrese, Massimiliano
    De Stefano, Nicola
    Eshaghi, Arman
    Filippi, Massimo
    Gasperini, Claudio
    Granziera, Cristina
    Kappos, Ludwig
    Rocca, Maria A.
    Rovira, Alex
    Sastre-Garriga, Jaume
    Sormani, Maria Pia
    Tur, Carmen
    Toosy, Ahmed T.
    NEUROLOGY, 2024, 103 (01)
  • [24] Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis
    Kappos, L.
    Wolinsky, J. S.
    Giovannoni, G.
    Arnold, D. L.
    Lublin, F.
    Wang, Q.
    Model, F.
    Wei, W.
    Garren, H.
    Manfrini, M.
    Belachew, S.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 309 - 310
  • [25] Relapse associated worsening and progression independent of relapse according to age in multiple sclerosis
    Iaffaldano, P.
    Lucisano, G.
    Manni, A.
    Simone, M.
    Paolicelli, D.
    Romeo, M.
    Morra, V. Brescia
    Patti, F.
    Zaffaroni, M.
    Gasperini, C.
    De Luca, G.
    Ferraro, D.
    Granella, F.
    Pozzilli, C.
    Romano, S.
    Gallo, P.
    Bergamaschi, R.
    Coniglio, M. G.
    Lus, G.
    Vianello, M.
    Banfi, P.
    Amato, M. P.
    Filippi, M.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 452 - 453
  • [26] Relapse-independent multiple sclerosis progression under natalizumab
    Graf, Jonas
    Leussink, Verena, I
    Soncin, Giulia
    Lepka, Klaudia
    Meinl, Ingrid
    Kumpfel, Tania
    Meuth, Sven G.
    Hartung, Hans-Peter
    Havla, Joachim
    Aktas, Orhan
    Albrecht, Philipp
    BRAIN COMMUNICATIONS, 2021, 3 (04)
  • [27] Progression independent of relapse activity in early multiple sclerosis patients and risk of secondary progression: an Italian multicentre study
    Portaccio, E.
    Bellinvia, A.
    Fonderico, M.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Clerici, V. L. A. Torri
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G.
    Morra, V. Brescia
    Ragonese, P.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 203 - 204
  • [28] Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis
    Rosenstein, Igal
    Nordin, Anna
    Sabir, Hemin
    Malmestrom, Clas
    Blennow, Kaj
    Axelsson, Markus
    Novakova, Lenka
    JOURNAL OF NEUROLOGY, 2024, 271 (07) : 4412 - 4422
  • [29] Progression independent of relapse activity in paediatric, adult and late-onset multiple sclerosis patients
    Bellinvia, A.
    Portaccio, E.
    Fonderico, M.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Confalonieri, P.
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G. T.
    Morra, V. Brescia
    Salemi, G.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 95 - 96
  • [30] Effect of ofatumumab treatment on disability progression independent of relapse activity in patients with relapsing multiple sclerosis
    Kappos, L.
    Montalban, X.
    Cohen, J. A.
    Comi, G.
    Coyle, P. K.
    Li, B.
    Sfikas, N.
    Willi, R.
    Haring, D. A.
    Merschhemke, M.
    Hauser, S. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 47 - 47